Merck and The Michael J. Fox Foundation for Parkinson’s Research, MJFF, are advancing research aimed at slowing progression of Parkinson’s disease, PD. Through funding from MJFF’s “Biomarkers to Support Therapeutic Trials Program”, Merck’s SMCxPRO immunoassay technology has been used to help detect low levels of a biomarker associated with cell dysfunction in patients. Now, the service is available to the scientific community through support from the MJFF. This will make it possible to track the response of different therapeutic options to disease progression.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- FDA Approves Merck’s (MRK) New Vaccine, Capvaxive
- MRK, ABBV, LI: 3 Low-Beta Stocks with Upside Potential
- Analysts and Technical Indicators Agree: These 3 Stocks Are “Strong Buys” – 6/7/2024
- Coherus Biosciences appoints Karachun to board of directors
- Merus price target raised to $91 from $84 at BMO Capital